PT-141 (Bremelanotide)
bremelanotidevyleesi
Melanocortin agonist — sexual response. On/off effect profile; common attribution errors to avoid.
- Half-life
- 2.7 h
- Out of system
- ~14 h
- Route
- Subcutaneous
- Level
- Intermediate
Short-acting — protocols usually dose daily. After the last dose, roughly 97% has cleared in ~14 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What PT-141 (Bremelanotide) is used for
- Approved (as Bremelanotide / Vyleesi) for female hypoactive sexual desire
- Works centrally on melanocortin, not vascular like PDE-5 inhibitors
- On-demand profile: take, wait, off
How it's typically used
Approved: 1.75 mg subcutaneous as needed, max once per 24 h, no more than 8/month.
What to watch for
- Nausea + flushing are the dominant side effects
- Transient blood-pressure increases — caution with hypertension
- Not for cardiovascular disease without clearance
About Other research compounds
- What they are
- Nootropics, metabolic agents, and research compounds that don't fit the other classes.
- How they're run
- Route and schedule vary widely — check the individual entry.
- What to watch
- This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.
Full guide
PT-141 (Bremelanotide): Tracking Doses and Side Effects
PT-141 has a distinctive on/off effect profile that needs a different tracking pattern. What to log, when to log it, and the common attribution errors.
Other other research compounds
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.